Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to irinotecan combination chemotherapy

被引：11

作者：

An, Xin ^{[1
,2
]}

Ding, Pei-Rong ^{[1
,3
]}

Xiang, Xiao-Juan ^{[1
,2
]}

Wang, Zhi-Qiang ^{[1
,2
]}

Wang, Feng-Hua ^{[1
,2
]}

Feng, Fen ^{[1
,2
]}

Jiang, Wen-Qi ^{[1
,2
]}

He, You-Jian ^{[1
,2
]}

Xu, Rui-Hua ^{[1
]}

Li, Yu-Hong ^{[1
,2
]}

机构：

[1] State Key Lab Oncol S China, Guangzhou, Guangdong, Peoples R China

[2] Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou 510275, Guangdong, Peoples R China

[3] Sun Yat Sen Univ, Ctr Canc, Dept Colorectal Surg, Guangzhou, Guangdong, Peoples R China

来源：

BIOMARKERS | 2010年 / 15卷 / 03期

关键词：

Carcinoembryonic antigen surge; chemotherapy; irinotecan; metastatic colorectal cancer; FOLINIC ACID; COLON-CANCER; TUMOR-MARKER; CEA; EXPRESSION; 5-FLUOROURACIL; OXALIPLATIN; THERAPY; CELLS; INCREASE;

D O I：

10.3109/13547500903477377

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Methods: We retrospectively reviewed 132 patients with metastatic colorectal cancer treated with irinotecan-based chemotherapy. Incidence of a CEA surge and chemotherapy efficacy were investigated. Results: Eleven of 99 eligible patients (11.1%) had CEA surges. None of the 11 patients showed progressive disease (four had a partial response, seven had stable disease). Conclusion: A CEA surge can be induced by irinotecan-based chemotherapy. An early increase in CEA after irinotecan-based chemotherapy does not usually indicate progression of disease and failure of therapy, and should not lead to a change of chemotherapy.

引用

页码：243 / 248

页数：6

共 50 条

[21] CARCINOEMBRYONIC ANTIGEN - CLINICAL CORRELATION WITH CHEMOTHERAPY FOR METASTATIC GASTROINTESTINAL CANCER
SKARIN, AT
DELWICHE, R
ZAMCHECK, N
LOKICH, JJ
FREI, E
CANCER, 1974, 33 (05) : 1239 - 1245
[22] EFFICACY OF BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY WITH IRINOTECAN AND CAPECITABINE (XELIRI) IN FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER
Ocvirk, J.
Rebersek, M.
Boc, M.
ANNALS OF ONCOLOGY, 2008, 19 : 129 - 129
[23] CARCINOEMBRYONIC ANTIGEN (CEA) AS A MONITOR OF CHEMOTHERAPY IN DISSEMINATED COLORECTAL CANCER
MAYER, RJ
GARNICK, MB
STEELE, GD
ZAMCHECK, N
CANCER, 1978, 42 (03) : 1428 - 1433
[24] LEUKOCYTE ALKALINE-PHOSPHATASE AND CARCINOEMBRYONIC ANTIGEN IN METASTATIC COLORECTAL-CANCER PATIENTS
WALACH, N
GUTERMAN, A
ZAIDMAN, JL
KAUFMAN, S
WEIMBERGER, L
SCHARF, S
TUMORI, 1991, 77 (02) : 164 - 166
[25] Phase I trial of polynucleotide immunization to carcinoembryonic antigen in patients with metastatic colorectal cancer
Conry, RM
Strong, TV
White, SA
Khazaeli, MB
LoBuglio, AF
Curiel, DT
CANCER GENE THERAPY, 1997, 4 (06) : O126 - O126
[26] EIA versus RIA in detecting carcinoembryonic antigen level of patients with metastatic colorectal cancer
Wang, WS
Lin, JK
Lin, TC
Chiou, TJ
Liu, JH
Yen, CC
Chen, WS
Jiang, JK
Yang, SH
Wang, HS
Chen, PM
HEPATO-GASTROENTEROLOGY, 2004, 51 (55) : 136 - 141
[27] Combination of irinotecan and other drugs in the treatment of colorectal metastatic cancer
Ducreux, M
Gil-Delgado, M
André, T
Ychou, M
de Gramond, A
Khayat, D
BULLETIN DU CANCER, 1998, : 43 - 46
[28] Current place of high-dose irinotecan chemotherapy in patients with metastatic colorectal cancer
Mohamed Hebbar
Marc Ychou
Michel Ducreux
Journal of Cancer Research and Clinical Oncology, 2009, 135 : 749 - 752
[29] Current place of high-dose irinotecan chemotherapy in patients with metastatic colorectal cancer
Hebbar, Mohamed
Ychou, Marc
Ducreux, Michel
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2009, 135 (06) : 749 - 752
[30] COMBINATION CHEMOTHERAPY WITH BIWEEKLY CETUXIMAB AND IRINOTECAN FOR WILD-TYPE KRAS METASTATIC COLORECTAL CANCER, REFRACTORY TO BOTH OXALIPLATIN AND IRINOTECAN
Barbosa, Caroline
Sousa, Romulado
Sabbaga, Jorge
Cotti, Guilherme
Saragiotto, Daniel
Hoff, Paulo
ANNALS OF ONCOLOGY, 2011, 22 : v103 - v103

← 1 2 3 4 5 →